Skip to main content
Top
Published in: Arthritis Research & Therapy 2/2000

01-02-2000 | Commentary

A revival of the B cell paradigm for rheumatoid arthritis pathogenesis?

Authors: Christophe Benoist, Diane Mathis

Published in: Arthritis Research & Therapy | Issue 2/2000

Login to get access

Abstract

Dominant paradigms for the understanding of rheumatoid arthritis (RA) pathogenesis have changed over the years. A predominant role of B lymphocytes, and perhaps of the rheumatoid factor they produced, was initially invoked. In more recent years, recognition of antigens in the joint by T cells sparking an inflammatory cascade has been a more favored interpretation. Here, we re-examine some of the arguments that underpin this proposed role of joint T cells, in light of recent results from transgenic mice in which a self-reactive T-cell receptor provokes disease, but from outside the joint and indirectly via B lymphocytes and immunoglobulins.
Literature
1.
go back to reference Zvaifler NJ: The immunopathology of joint inflammation in rheumatoid arthritis. Adv Immunol. 1973, 265: 265-336.CrossRef Zvaifler NJ: The immunopathology of joint inflammation in rheumatoid arthritis. Adv Immunol. 1973, 265: 265-336.CrossRef
2.
go back to reference Ohno O, Cooke D: Electron microscopic morphology of immunoglobulin aggregates and their interactions in rheumatoid articular collagenous tissues. Arthritis Rheum. 1978, 21: 516-527.PubMedCrossRef Ohno O, Cooke D: Electron microscopic morphology of immunoglobulin aggregates and their interactions in rheumatoid articular collagenous tissues. Arthritis Rheum. 1978, 21: 516-527.PubMedCrossRef
4.
go back to reference Vaughan JH: Pathogenic concepts and origins of rheumatoid factor in rheumatoid arthritis. Arthritis Rheum. 1993, 36: 1-6.PubMedCrossRef Vaughan JH: Pathogenic concepts and origins of rheumatoid factor in rheumatoid arthritis. Arthritis Rheum. 1993, 36: 1-6.PubMedCrossRef
5.
go back to reference Smolen JS, Steiner G: Are autoantibodies active players or epiphenomena?. Curr Opin Rheumatol. 1998, 10: 201-206.PubMedCrossRef Smolen JS, Steiner G: Are autoantibodies active players or epiphenomena?. Curr Opin Rheumatol. 1998, 10: 201-206.PubMedCrossRef
6.
go back to reference Panayi GS, Lanchbury JS, Kingsley GH: The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum. 1992, 35: 729-735.PubMedCrossRef Panayi GS, Lanchbury JS, Kingsley GH: The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum. 1992, 35: 729-735.PubMedCrossRef
7.
go back to reference De Keyser F, Elewaut D, Vermeersch J, De : The role of T cells in rheumatoid arthritis. Clin Rheumatol. 1995, 14 (suppl 2): 5-9.CrossRef De Keyser F, Elewaut D, Vermeersch J, De : The role of T cells in rheumatoid arthritis. Clin Rheumatol. 1995, 14 (suppl 2): 5-9.CrossRef
8.
go back to reference Fox DA: The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives. Arthritis Rheum. 1997, 40: 598-609.PubMedCrossRef Fox DA: The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives. Arthritis Rheum. 1997, 40: 598-609.PubMedCrossRef
9.
go back to reference Firestein GS, Zvaifler NJ: How important are T cells in chronic rheumatoid synovitis?. Arthritis Rheum. 1990, 33: 768-773.PubMedCrossRef Firestein GS, Zvaifler NJ: How important are T cells in chronic rheumatoid synovitis?. Arthritis Rheum. 1990, 33: 768-773.PubMedCrossRef
10.
go back to reference Thomas R, Lipsky PE: Could endogenous self-peptides presented by dendritic cells initiate rheumatoid arthritis?. Immunol Today. 1996, 17: 559-564. 10.1016/S0167-5699(96)20030-1.PubMedCrossRef Thomas R, Lipsky PE: Could endogenous self-peptides presented by dendritic cells initiate rheumatoid arthritis?. Immunol Today. 1996, 17: 559-564. 10.1016/S0167-5699(96)20030-1.PubMedCrossRef
11.
go back to reference McMichael AJ, Sasazuki T, McDevitt HO, Payne RO: Increased frequency of HLA-Cw3 and HLA-Dw4 in rheumatoid arthritis. Arthritis Rheum. 1977, 20: 1037-1042.PubMedCrossRef McMichael AJ, Sasazuki T, McDevitt HO, Payne RO: Increased frequency of HLA-Cw3 and HLA-Dw4 in rheumatoid arthritis. Arthritis Rheum. 1977, 20: 1037-1042.PubMedCrossRef
12.
go back to reference Goronzy J, Weyand CM, Fathman CG: Shared T cell recognition sites on human histocompatibility leukocyte antigen class II molecules of patients with seropositive rheumatoid arthritis. J Clin Invest . 1986, 77: 1042-1049.PubMedPubMedCentralCrossRef Goronzy J, Weyand CM, Fathman CG: Shared T cell recognition sites on human histocompatibility leukocyte antigen class II molecules of patients with seropositive rheumatoid arthritis. J Clin Invest . 1986, 77: 1042-1049.PubMedPubMedCentralCrossRef
13.
go back to reference Paliard X, West SG, Lafferty JA: Evidence for the effects of a superantigen in rheumatoid arthritis. Science. 1991, 253: 325-329.PubMedCrossRef Paliard X, West SG, Lafferty JA: Evidence for the effects of a superantigen in rheumatoid arthritis. Science. 1991, 253: 325-329.PubMedCrossRef
14.
go back to reference Struyk L, Hawes GE, Chatila MK: T cell receptors in rheumatoid arthritis. Arthritis Rheum. 1995, 38: 577-589.PubMedCrossRef Struyk L, Hawes GE, Chatila MK: T cell receptors in rheumatoid arthritis. Arthritis Rheum. 1995, 38: 577-589.PubMedCrossRef
15.
go back to reference Harris ED: Etiology and pathogenesis of rheumatoid arthritis. In: Rheumatoid Arthritis, 4th ed. Edited by Kelley W, Harris E, Ruddy S, Sledge C. Philadelphia, PA: WB Saunders Co. 1993, 833-873. Harris ED: Etiology and pathogenesis of rheumatoid arthritis. In: Rheumatoid Arthritis, 4th ed. Edited by Kelley W, Harris E, Ruddy S, Sledge C. Philadelphia, PA: WB Saunders Co. 1993, 833-873.
16.
go back to reference Kotzin BL, Kappler J: Targeting the T cell receptor in rheumatoid arthritis. Arthritis Rheum. 1998, 41: 1906-1910. 10.1002/1529-0131(199811)41:11<1906::AID-ART3>3.3.CO;2-8.PubMedCrossRef Kotzin BL, Kappler J: Targeting the T cell receptor in rheumatoid arthritis. Arthritis Rheum. 1998, 41: 1906-1910. 10.1002/1529-0131(199811)41:11<1906::AID-ART3>3.3.CO;2-8.PubMedCrossRef
17.
go back to reference Kouskoff V, Korganow A-S, Duchatelle V: Organ-specific disease provoked by systemic autoreactivity. Cell. 1996, 87: 811-822.PubMedCrossRef Kouskoff V, Korganow A-S, Duchatelle V: Organ-specific disease provoked by systemic autoreactivity. Cell. 1996, 87: 811-822.PubMedCrossRef
18.
go back to reference Korganow A-S, Ji H, Mangialaio S: From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity. 1999, 10: 451-461.PubMedCrossRef Korganow A-S, Ji H, Mangialaio S: From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity. 1999, 10: 451-461.PubMedCrossRef
19.
go back to reference Holmdahl R: Autoimmunity: another pathway towards arthritis. Curr Biol. 1999, 9: R528-R530. 10.1016/S0960-9822(99)80328-5.PubMedCrossRef Holmdahl R: Autoimmunity: another pathway towards arthritis. Curr Biol. 1999, 9: R528-R530. 10.1016/S0960-9822(99)80328-5.PubMedCrossRef
20.
go back to reference Ji H, Korganow AS, Mangialaio S: Different modes of pathogenesis in T-cell-dependent autoimmunity: clues from two TCR transgenic systems. Immunol Rev. 1999, 169: 139-146.PubMedCrossRef Ji H, Korganow AS, Mangialaio S: Different modes of pathogenesis in T-cell-dependent autoimmunity: clues from two TCR transgenic systems. Immunol Rev. 1999, 169: 139-146.PubMedCrossRef
21.
go back to reference Matsumoto I, Staub A, Benoist C, Mathis D: Arthritis provoked by linked T and B cell recognition a glycolytic enzyme. Science. 1999, 286: 1732-1735. 10.1126/science.286.5445.1732.PubMedCrossRef Matsumoto I, Staub A, Benoist C, Mathis D: Arthritis provoked by linked T and B cell recognition a glycolytic enzyme. Science. 1999, 286: 1732-1735. 10.1126/science.286.5445.1732.PubMedCrossRef
22.
go back to reference Stuart JM, Cremer MA, Townes AS, Kang AH: Type II collagen-induced arthritis in rats. Passive transfer with serum and evidence that IgG anticollagen antibodies can cause arthritis. J Exp Med. 1982, 155: 1-16.PubMedCrossRef Stuart JM, Cremer MA, Townes AS, Kang AH: Type II collagen-induced arthritis in rats. Passive transfer with serum and evidence that IgG anticollagen antibodies can cause arthritis. J Exp Med. 1982, 155: 1-16.PubMedCrossRef
23.
go back to reference Weinblatt ME, Maddison PJ, Bulpitt KJ: CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. Arthritis Rheum. 1995, 38: 1589-1594.PubMedCrossRef Weinblatt ME, Maddison PJ, Bulpitt KJ: CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. Arthritis Rheum. 1995, 38: 1589-1594.PubMedCrossRef
24.
go back to reference Moreland LW, Heck LW, Koopman WJ: Biologic agents for treating rheumatoid arthritis. Arthritis Rheum. 1997, 40: 397-409.PubMedCrossRef Moreland LW, Heck LW, Koopman WJ: Biologic agents for treating rheumatoid arthritis. Arthritis Rheum. 1997, 40: 397-409.PubMedCrossRef
25.
go back to reference Berek C, Kim HJ: B-cell activation and development within chronically inflamed synovium in rheumatoid and reactive arthritis. Semin Immunol. 1997, 9: 261-268. 10.1006/smim.1997.0076.PubMedCrossRef Berek C, Kim HJ: B-cell activation and development within chronically inflamed synovium in rheumatoid and reactive arthritis. Semin Immunol. 1997, 9: 261-268. 10.1006/smim.1997.0076.PubMedCrossRef
Metadata
Title
A revival of the B cell paradigm for rheumatoid arthritis pathogenesis?
Authors
Christophe Benoist
Diane Mathis
Publication date
01-02-2000
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 2/2000
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar73

Other articles of this Issue 2/2000

Arthritis Research & Therapy 2/2000 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine